ICER president Steven Pearson at JPM23 (Adrien Villez for Endpoints News)
April 12, 2023 04:24 PM EDTUpdated 05:30 PM
Pharma
Cell/Gene Tx

At $2M per shot, ICER says two new sick­le cell gene ther­a­pies could be cost-ef­fec­tive

Zachary Brennan

Senior Editor

Gene ther­a­pies ap­proved by the FDA have so far brought with them eye-pop­ping prices of $2 mil­lion or more be­cause of the ex­tra­or­di­nary sav­ings, some­times …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times